专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050260678A1 Method of diagnosing nephrotic syndrome 失效
标题翻译：诊断肾病综合征的方法
公开(公告)号：US20050260678A1
公开(公告)日：2005-11-24
申请号：US10487978
申请日：2002-08-29
申请人： Naohisa Tomosugi , Mieko Shiwa , Kenji Saito
发明人： Naohisa Tomosugi , Mieko Shiwa , Kenji Saito
IPC分类号： G01N33/53 , G01N33/68
CPC分类号： G01N33/6851 , G01N33/6848 , G01N33/6893 , G01N33/6896 , G01N2800/347 , Y10S436/811 , Y10T436/25
摘要： This invention provides organic biomolecule markers (e.g., proteins) useful for differentiating minimal change nephrotic syndrome (MCNS) from focal segmental glomerulosclerosis (FCS), membranous nephrothropy (MN), and membranoproliferative glomerulonephritis (MPGN). This invention also provides organic biomolecule markers useful for evaluating the therapeutic value of agents for treating kidney disease.
摘要翻译：本发明提供了可用于区分局灶性节段性肾小球硬化（FCS），膜性肾病（MN）和膜增生性肾小球肾炎（MPGN）的最小变化肾病综合征（MCNS）的有机生物分子标志物（例如蛋白质）。本发明还提供了可用于评估用于治疗肾脏疾病的药剂的治疗价值的有机生物分子标志物。

2. 发明申请

US20120115935A1 ANTI-CANCER AGENT, METHOD FOR INDUCING APOPTOSIS OF CANCER CELLS, AND METHOD FOR SCREENING FOR ANTI-CANCER AGENT 审中-公开
标题翻译：抗癌剂，诱导癌细胞凋亡的方法和用于筛选抗癌剂的方法
公开(公告)号：US20120115935A1
公开(公告)日：2012-05-10
申请号：US13384102
申请日：2010-07-14
申请人： Yasuhito Ishigaki , Naohisa Tomosugi
发明人： Yasuhito Ishigaki , Naohisa Tomosugi
IPC分类号： A61K31/713 , A61P35/00 , C12Q1/68 , C07H21/02 , C12N5/02
CPC分类号： A61K31/7088 , A61K31/713 , C12N15/113 , C12N2310/14
摘要： Disclosed is an anti-cancer agent which can inhibit the progression of cell cycle in the M phase, unlike taxane anti-cancer agents. The anti-cancer agent comprises a compound capable of inhibiting specifically the expression and/or functions of RBM8A depicted in SEQ ID NO: 1, Magoh depicted in SEQ ID NO: 3 or an isoform thereof. The anti-cancer agent can inhibit the expression and/or functions of RBM8A or Magoh in cancer cells to terminate the cell cycle in the M phase, thereby inhibiting the proliferation of the cells. Therefore, the anti-cancer agent can inhibit the proliferation of cancer cells and induce the apoptosis of cancer cells, leading to the cure of cancer.
摘要翻译：公开了与紫杉烷类抗癌剂不同的是可抑制M期细胞周期进展的抗癌剂。抗癌剂包括能够特异性抑制SEQ ID NO：1所示的RBM8A，SEQ ID NO：3所示的Magoh或其同种型的表达和/或功能的化合物。抗癌剂可以抑制癌细胞中RBM8A或Magoh的表达和/或功能，从而终止M期的细胞周期，从而抑制细胞的增殖。因此，抗癌剂可以抑制癌细胞的增殖，诱导癌细胞凋亡，导致癌症的治愈。

3. 发明申请

US20100298159A1 Diagnostic methods for acute ischemic disease using activated hepcidin as an indicator 失效
标题翻译：使用活化的铁调素作为指标的急性缺血性疾病的诊断方法
公开(公告)号：US20100298159A1
公开(公告)日：2010-11-25
申请号：US12601955
申请日：2008-05-30
申请人： Naohisa Tomosugi
发明人： Naohisa Tomosugi
IPC分类号： C40B30/04
CPC分类号： G01N33/6893 , G01N33/6848 , G01N2800/2871 , G01N2800/324 , G01N2800/325
摘要： An objective of the present invention is to provide methods of testing for acute ischemic diseases using active hepcidin as an indicator, methods for determining the timing to administer an agent for treating the disease, and kits for these methods.To accomplish the above-mentioned objective, the present inventors analyzed the serum proteome patterns characteristic of acute myocardial infarction patients using SELDI-TOF-MS. As a result, it was found that hepcidin-20 has a very high correlation with acute myocardial infarction. Furthermore, the present inventors discovered that at the time of disease onset, the blood concentration of hepcidin-20 rises sharply in particular, and shows high levels within six hours, especially four hours of onset. The present invention enables early diagnosis of acute ischemic diseases.
摘要翻译：本发明的目的是提供使用活性铁调素作为指标来测试急性缺血性疾病的方法，用于确定施用治疗疾病的药剂的时间的方法，以及这些方法的试剂盒。为了实现上述目的，本发明人使用SELDI-TOF-MS分析了急性心肌梗死患者的血清蛋白质组图谱特征。结果发现，hepcidin-20与急性心肌梗死的相关性非常高。此外，本发明人发现，在疾病发病时，铁调素-20的血药浓度特别上升，在6小时以上，特别是4小时开始时显示高水平。本发明能够早期诊断急性缺血性疾病。

4. 发明授权

US08187827B2 Diagnostic methods for acute ischemic disease using activated hepcidin as an indicator 失效
标题翻译：使用活化的铁调素作为指标的急性缺血性疾病的诊断方法
公开(公告)号：US08187827B2
公开(公告)日：2012-05-29
申请号：US12601955
申请日：2008-05-30
申请人： Naohisa Tomosugi
发明人： Naohisa Tomosugi
IPC分类号： G01N33/55
CPC分类号： G01N33/6893 , G01N33/6848 , G01N2800/2871 , G01N2800/324 , G01N2800/325
摘要： An objective of the present invention is to provide methods of testing for acute ischemic diseases using active hepcidin as an indicator, methods for determining the timing to administer an agent for treating the disease, and kits for these methods. To accomplish the objective, the present inventors analyzed the serum proteome patterns characteristic of acute myocardial infarction patients using SELDI-TOF-MS. As a result, it was found that hepcidin-20 has a very high correlation with acute myocardial infarction. Furthermore, the present inventors discovered that at the time of disease onset, the blood concentration of hepcidin-20 rises sharply in particular, and shows high levels within six hours, especially four hours of onset. The present invention enables early diagnosis of acute ischemic diseases.
摘要翻译：本发明的目的是提供使用活性铁调素作为指标来测试急性缺血性疾病的方法，用于确定施用治疗疾病的药剂的时间的方法，以及这些方法的试剂盒。为了达到目的，本发明人使用SELDI-TOF-MS分析了急性心肌梗死患者血清蛋白质组学特征。结果发现，hepcidin-20与急性心肌梗死的相关性非常高。此外，本发明人发现，在疾病发病时，铁调素-20的血药浓度特别上升，在6小时以上，特别是4小时开始时显示高水平。本发明能够早期诊断急性缺血性疾病。

5. 发明申请

US20110053268A1 METHOD FOR DIAGNOSIS OF ABNORMAL IRON METABOLISM USING ACTIVE HEPCIDIN AS INDICATOR 审中-公开
标题翻译：使用活性头孢氨酸作为指示剂诊断异常铁代谢的方法
公开(公告)号：US20110053268A1
公开(公告)日：2011-03-03
申请号：US12311842
申请日：2007-03-16
申请人： Naohisa Tomosugi
发明人： Naohisa Tomosugi
IPC分类号： C12N5/0789 , G01N33/50 , C07K14/575 , C07K7/08 , C07K16/18 , H01J49/00 , G01N33/68
CPC分类号： G01N33/6851 , G01N33/74
摘要： The present inventor employed surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) to analyze distinctive serum proteomic patterns of hemodialysis patients. The present inventor found three peptides at 2,192, 2,789, and 2,851 m/z that showed a significant correlation with the levels of serum ferritin. The molecular sizes of the 2,192 and 2,789 m/z matched well with the reported sizes of hepcidin-20 and -25, respectively, and the latter completely coincided with the size of synthetic hepcidin-25. It would be possible to diagnose abnormal iron metabolism by detecting bioactive forms of hepcidin in the serum.
摘要翻译：本发明人使用表面增强激光解吸/电离飞行时间质谱（SELDI-TOF-MS）来分析血液透析患者的特征性血清蛋白质组学模式。本发明人发现，在2,192,2,789和2,851m / z的三种肽与血清铁蛋白水平显着相关。 2,192和2,789 m / z的分子大小分别与报道的hepcidin-20和-25的大小匹配，后者完全与合成的铁调素-25的大小一致。通过检测血清中铁调素的生物活性形式，可以诊断铁代谢异常。

6. 发明授权

US07297556B2 Method of diagnosing nephrotic syndrome 失效
标题翻译：诊断肾病综合征的方法
公开(公告)号：US07297556B2
公开(公告)日：2007-11-20
申请号：US10487978
申请日：2002-08-29
申请人： Naohisa Tomosugi
发明人： Naohisa Tomosugi
IPC分类号： G01N33/53
CPC分类号： G01N33/6851 , G01N33/6848 , G01N33/6893 , G01N33/6896 , G01N2800/347 , Y10S436/811 , Y10T436/25
摘要： This invention provides organic biomolecule markers (e.g., proteins) useful for differentiating minimal change nephrotic syndrome (MCNS) from focal segmental glomerulosclerosis (FCS), membranous nephrothropy (MN), and membranoproliferative glomerulonephritis (MPGN). This invention also provides organic biomolecule markers useful for evaluating the therapeutic value of agents for treating kidney disease.
摘要翻译：本发明提供了可用于区分局灶性节段性肾小球硬化（FCS），膜性肾病（MN）和膜增生性肾小球肾炎（MPGN）的最小变化肾病综合征（MCNS）的有机生物分子标志物（例如蛋白质）。本发明还提供了可用于评估用于治疗肾脏疾病的药剂的治疗价值的有机生物分子标志物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式